Abstract
Aim: To investigate the therapeutic potential of mebendazole (MBZ)-loaded nanostructured lipid carriers (NLCs). Methodology: NLC-MBZ was prepared and characterized to evaluate the in vitro and in vivo anticancer effects and the inhibitory effect on RanGTP and its potential as an antimetastatic treatment in vivo. Results: NLC-MBZ exhibited a size and charge of 155±20nm and-27±0.5mV, respectively, with 90.7% encapsulation. Free MBZ and NLC-MBZ had a 50% inhibitory concentrationof 610 and 305nM, respectively, against MDA-MB-231 cell lines. NLC-MBZ decreasedtumor size, suppressed tumor lung metastases, and lowered the expression of CDC25A, SKP2, RbX1and Cullin1while boosting the Rb proteins. Conclusion: NLC-MBZ displayedantiangiogenic potential and resulted in a reduced rate of lung metastasis in vivo.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
